Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Remus PharmaceuticalsNSE:REMUS +0.61%56 5-Year Yield-on-Cost % is 0.14 as of Jul. 29, 2026, which is 40% above its 10-year median of 0.10. GuruFocus rates NSE:REMUS with a GF Score™ of 56/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 69 Medical Distribution companies, Remus Pharmaceuticals ranks worse than 97.1% on this metric.
Remus Pharmaceuticals's yield on cost for the quarter that ended in Mar. 2026 was 0.14.
The historical rank and industry rank for Remus Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:REMUS'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.04 Med: 0.1 Max: 0.16
Current: 0.14
During the past 7 years, Remus Pharmaceuticals's highest Yield on Cost was 0.16. The lowest was 0.04. And the median was 0.10.
NSE:REMUS's 5-Year Yield-on-Cost % is ranked worse than 97.1% of 69
companies
in the Medical Distribution industry
Industry Median: 3.09
vs NSE:REMUS: 0.14
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Remus Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
NSE:REMUS vs MCK, COR, CAH: 5-Year Yield-on-Cost % Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals 5-Year Yield-on-Cost % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Remus Pharmaceuticals (NSE:REMUS) has a 5-Year Yield-on-Cost % of 0.14 as of Jul. 29, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Remus Pharmaceuticals and its competitors. This is 40% above median its historical median of 0.10. Over the past decade, Remus Pharmaceuticals' 5-Year Yield-on-Cost % has ranged from 0.04 to 0.16. According to the industry distribution chart, Remus Pharmaceuticals ranks #67 out of 69 companies in the Medical Distribution industry, placing it in the top 97.1%.
Is Remus Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Remus Pharmaceuticals' current 5-Year Yield-on-Cost % of 0.14 is 40% above median its 10-year median of 0.10. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.16. The Medical Distribution industry median 5-Year Yield-on-Cost % is 3.09. Remus Pharmaceuticals' value of 0.14 is 95.5% below this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #67 out of 69 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Remus Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' 5-Year Yield-on-Cost % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #67 out of 69 companies for 5-Year Yield-on-Cost %. This places Remus Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 3.09. Remus Pharmaceuticals' value of 0.14 is 95.5% below this benchmark. Historically, Remus Pharmaceuticals' own 5-Year Yield-on-Cost % has ranged from 0.04 to 0.16 over the past decade. While the company's 10-year median is 0.10 vs. the industry median of 3.09, Remus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Distribution company?
The median 5-Year Yield-on-Cost % among Medical Distribution companies is 3.09, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current 5-Year Yield-on-Cost % of 0.14 is 95.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median 5-Year Yield-on-Cost % is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.14, which is 40% above median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹719.00 — trading 65.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.14, which is 40% above median its 10-year median of 0.10 and 95.5% below the Medical Distribution industry median of 3.09. Remus Pharmaceuticals' overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current 5-Year Yield-on-Cost % is 0.14 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹719.00 is trading 65.3% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
5-Year Yield-on-Cost %: 0.14 (40% above median its 10-year median of 0.10)
GF Value™: ₹2,071.36 vs. price of ₹719.00 (65.3% below fair value)
Industry Position: 95.5% below the Medical Distribution median (#67 of 69)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
56GF Score
Get the complete analysis for NSE:REMUS
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
